ANI Pharmaceuticals (ANIP) Projected to Post Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Friday, May 9th. Analysts expect ANI Pharmaceuticals to post earnings of $1.37 per share and revenue of $179.75 million for the quarter.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $70.69 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of $1.54 billion, a P/E ratio of -128.53 and a beta of 0.49. The firm has a fifty day moving average of $65.24 and a 200-day moving average of $60.22. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $72.57.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This trade represents a 1.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now owns 80,145 shares in the company, valued at approximately $5,526,799.20. This trade represents a 0.50 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,200 shares of company stock worth $197,792. Insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, April 24th. Guggenheim restated a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Friday, April 11th. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They set a “buy” rating and a $80.00 price objective on the stock. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price for the company. Finally, Truist Financial raised their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a report on Monday, April 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $80.13.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.